Prelude Therapeutics Incorporated

    Jurisdiction
    United States
    ISIN
    US74065P1012 (PRLD)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. Read full profile

    Fundamentals

    Net revenue
    €5.97M
    Gross margin
    93.8%
    EBIT
    -€115.15M
    EBIT margin
    -1,928.7%
    Net income
    -€106.04M
    Net margin
    -1,776.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 657K $504.35K +22K Buy

    Earnings Calls

    Add to watchlist

    Notifications